Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Go back to Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis| Johnson & Johnson (NYSE: JNJ) | Delayed: 255.63 +5.02 (2.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $250.61 | 52 Week High | $126.07 | |||
| Open | $252.76 | 52 Week Low | $94.28 | |||
| Day High | $256.29 | P/E | 53.15 | |||
| Day Low | $251.21 | EPS | $4.81 | |||
| Volume | 9,100,127 | |||||
